RxDoctor Payments Data

William Bruner, DO

Obstetrics & Gynecology · Sandusky, OHNPI 1730134446

Payments from drug & device makers

$5,157in general payments, 2019–2025

Across 270 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$906
  • Organon$505
  • Astellas Pharma US Inc$487
  • Amgen$369
  • Exeltis, USA Inc.$336
  • Sumitomo Pharma America, Inc.$236
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,96296%
  • Education$1954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,157 in reported general payments places this provider in the 85th percentile of 1,376 obstetrics & gynecology providers in Ohio.

See all obstetrics & gynecology providers in Ohio

Medicare billing

Part B allowed, 2024
$48,398
Medicare patients
362
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated57$27,883
MyrbetriqMirabegron26$27,783
Estradiol205$5,531
Oxybutynin Chloride ErOxybutynin Chloride170$4,798
Raloxifene Hcl51$2,298
Estradiol (Once Weekly)Estradiol15$2,099
Estradiol (Twice Weekly)Estradiol15$1,325
Ibandronate Sodium31$1,155
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$716
Fluconazole22$587
ValacyclovirValacyclovir Hcl20$550
Oxybutynin Chloride23$285
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet14$261
Solifenacin Succinate13$249
Alendronate Sodium26$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$188$27,88357 claims
Astellas Pharma US IncMyrbetriq$487$27,78326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,376 obstetrics & gynecology providers in Ohio.

Other obstetrics & gynecology in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →